Medical spas continue to expand beyond traditional aesthetic services, and peptides have quickly become one of the more heavily marketed offerings in this space. While these products are often positioned as part of a broader “wellness” model, the legal framework that governs them is far less flexible.
At the federal level, the key issue is not what a peptide is called, but what it is intended to do. If a peptide is administered with the purpose of affecting the structure or function of the body (or treating or preventing a condition) it will generally be regulated as a drug. That classification brings it right within the FDA’s approval and oversight requirements, which many peptide products currently on the market do not meet.
Compounding, the process of customizing formulations of peptide-based medications that are prepared by pharmacies, presents an additional compliance challenge. Many medspas source peptides through third-party compounding pharmacies, assuming that this alone ensures compliance. However, Section 503A limits what substances may be compounded for patient use, and the FDA has taken an active role in categorizing peptides based on safety concerns. Peptides that fall within “Category 1” may be compounded if all other statutory conditions are satisfied, but “Category 2” peptides are not permitted for human compounding at all. If a medspa is offering or administering a non-compliant compounded peptide, both the entity and its supervising providers could face scrutiny. In addition, reliance on “research use only” labeling will not mitigate that risk. Regulators consistently evaluate how a product is marketed, distributed, and ultimately used, not just how it is labeled on paper.
On April 15, the FDA issued a notice of its intent to remove one peptide from Category 1 and 12 peptides from Category 2. At the FDA’s Pharmacy Compounding Advisory Committee meeting in July of this year, these peptides will be considered for inclusion on the “503A Bulks List” of drugs that can be used in compounding. Medspas and other businesses that administer peptides should monitor the FDA’s “Bulk Drug Substances Nominated for Use in Compounding Under Section 503A” list for future changes.
The current regulatory environment suggests that peptides are unlikely to remain a gray area indefinitely. Increased enforcement activity, including a recent wave of FDA warning letters, and potential shifts in advisory committee priorities all point toward closer scrutiny in the near term.
Sign up to receive Rivkin Rounds at www.RivkinRounds.com.